Omar Saeed1, Rita Jermyn1, Faraj Kargoli1, Shivank Madan1, Santhosh Mannem1, Sampath Gunda1, Cecilia Nucci1, Sarah Farooqui1, Syed Hassan1, Allison Mclarty1, Michelle Bloom1, Ronald Zolty1, Julia Shin1, David D'Alessandro1, Daniel J Goldstein1, Snehal R Patel2. 1. From the Division of Cardiology, Department of Medicine (O.S., R.J., F.K., S.M., S.M., S.G., C.N., R.Z., J.S., S.R.P.) and Department of Cardiothoracic Surgery (D.D'A., D.J.G.), Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; and Division of Cardiology, Department of Medicine (S.F., S.H., M.B.) and Division of Cardiothoracic Surgery, Department of Surgery (A.M.), Stony Brook University, Long Island, NY. 2. From the Division of Cardiology, Department of Medicine (O.S., R.J., F.K., S.M., S.M., S.G., C.N., R.Z., J.S., S.R.P.) and Department of Cardiothoracic Surgery (D.D'A., D.J.G.), Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; and Division of Cardiology, Department of Medicine (S.F., S.H., M.B.) and Division of Cardiothoracic Surgery, Department of Surgery (A.M.), Stony Brook University, Long Island, NY. snepatel@montefiore.org.
Abstract
BACKGROUND: Adverse events (AEs), such as intracranial hemorrhage, thromboembolic event, and progressive aortic insufficiency, create substantial morbidity and mortality during continuous flow left ventricular assist device support yet their relation to blood pressure control is underexplored. METHODS AND RESULTS: A multicenter retrospective review of patients supported for at least 30 days and ≤18 months by a continuous flow left ventricular assist device from June 2006 to December 2013 was conducted. All outpatient Doppler blood pressure (DOPBP) recordings were averaged up to the time of intracranial hemorrhage, thromboembolic event, or progressive aortic insufficiency. DOPBP was analyzed as a categorical variable grouped as high (>90 mm Hg; n=40), intermediate (80-90 mm Hg; n=52), and controlled (<80 mm Hg; n=31). Cumulative survival free from an AE was calculated using Kaplan-Meier curves and Cox hazard ratios were derived. Patients in the high DOPBP group had worse baseline renal function, lower angiotensin-converting enzyme inhibitor or angiotensin receptor blocker usage during continuous flow left ventricular assist device support, and a more prevalent history of hypertension. Twelve (30%) patients in the high DOPBP group had an AE, in comparison with 7 (13%) patients in the intermediate DOPBP group and only 1 (3%) in the controlled DOPBP group. The likelihood of an AE increased in patients with a high DOPBP (adjusted hazard ratios [95% confidence interval], 16.4 [1.8-147.3]; P=0.012 versus controlled and 2.6 [0.93-7.4]; P=0.068 versus intermediate). Overall, a similar association was noted for the risk of intracranial hemorrhage (P=0.015) and progressive aortic insufficiency (P=0.078) but not for thromboembolic event (P=0.638). Patients with an AE had a higher DOPBP (90±10 mm Hg) in comparison with those without an AE (85±10 mm Hg; P=0.05). CONCLUSIONS: In a population at risk, higher DOPBP during continuous flow left ventricular assist device support was significantly associated with a composite of AEs.
BACKGROUND: Adverse events (AEs), such as intracranial hemorrhage, thromboembolic event, and progressive aortic insufficiency, create substantial morbidity and mortality during continuous flow left ventricular assist device support yet their relation to blood pressure control is underexplored. METHODS AND RESULTS: A multicenter retrospective review of patients supported for at least 30 days and ≤18 months by a continuous flow left ventricular assist device from June 2006 to December 2013 was conducted. All outpatient Doppler blood pressure (DOPBP) recordings were averaged up to the time of intracranial hemorrhage, thromboembolic event, or progressive aortic insufficiency. DOPBP was analyzed as a categorical variable grouped as high (>90 mm Hg; n=40), intermediate (80-90 mm Hg; n=52), and controlled (<80 mm Hg; n=31). Cumulative survival free from an AE was calculated using Kaplan-Meier curves and Cox hazard ratios were derived. Patients in the high DOPBP group had worse baseline renal function, lower angiotensin-converting enzyme inhibitor or angiotensin receptor blocker usage during continuous flow left ventricular assist device support, and a more prevalent history of hypertension. Twelve (30%) patients in the high DOPBP group had an AE, in comparison with 7 (13%) patients in the intermediate DOPBP group and only 1 (3%) in the controlled DOPBP group. The likelihood of an AE increased in patients with a high DOPBP (adjusted hazard ratios [95% confidence interval], 16.4 [1.8-147.3]; P=0.012 versus controlled and 2.6 [0.93-7.4]; P=0.068 versus intermediate). Overall, a similar association was noted for the risk of intracranial hemorrhage (P=0.015) and progressive aortic insufficiency (P=0.078) but not for thromboembolic event (P=0.638). Patients with an AE had a higher DOPBP (90±10 mm Hg) in comparison with those without an AE (85±10 mm Hg; P=0.05). CONCLUSIONS: In a population at risk, higher DOPBP during continuous flow left ventricular assist device support was significantly associated with a composite of AEs.
Authors: Stephen J Forest; Rongbing Xie; James K Kirklin; Jennifer Cowger; Yu Xia; Anne I Dipchand; Cumara Sivathasan; Chris Merry; Lars H Lund; Robert Kormos; Margaret M Hannan; Takeshi Nakatani; Ulrich Jorde; Daniel J Goldstein Journal: J Heart Lung Transplant Date: 2018-06-21 Impact factor: 10.247
Authors: Rayan Yousefzai; Michela Brambatti; Hao A Tran; Rachel Pedersen; Oscar Ö Braun; Tina Baykaner; Roxana Ghashghaei; Nasir Z Sulemanjee; Omar M Cheema; Matthew Rappelt; Carmela Baeza; Abdulaziz Alkhayyat; Yang Shi; Victor Pretorius; Barry Greenberg; Eric Adler; Vinay Thohan Journal: ASAIO J Date: 2020-04 Impact factor: 2.872
Authors: Pavol Sajgalik; Vaclav Kremen; Vratislav Fabian; Simon Maltais; John M Stulak; Sudhir S Kushwaha; Lyle D Joyce; John A Schirger; Bruce D Johnson Journal: ASAIO J Date: 2019-02 Impact factor: 2.872
Authors: Jennifer A Cowger; Palak Shah; Francis D Pagani; Gillan Grafton; John Stulak; Themistokles Chamogeorgakis; David Lanfear; Hassan Nemeh; Sean Pinney Journal: J Heart Lung Transplant Date: 2019-11-26 Impact factor: 10.247
Authors: William K Cornwell; Amrut V Ambardekar; Tomio Tran; Jay D Pal; Luis Cava; Justin Lawley; Takashi Tarumi; Christy L Cornwell; Keith Aaronson Journal: Stroke Date: 2019-02 Impact factor: 7.914